Travere Therapeutics (TVTX) Short-Term Debt issuances (2014)
Travere Therapeutics' (TVTX) quarterly Short-Term Debt issuances came in at -$42.4 million in Q4 2014, down 1272.27% on a QoQ basis from $3.6 million in Q3 2014.
Powered by 
Analysis
Travere Therapeutics (TVTX) Short-Term Debt issuances (2014) Analysis & Trends
Travere Therapeutics (TVTX) has 1 years of Short-Term Debt issuances data on file, last reported at -$42.4 million in Q4 2014.
- Quarterly Short-Term Debt issuances changed N/A year-over-year to -$42.4 million in Q4 2014, while the trailing twelve-month figure through Dec 2016 was -$38.8 million (changed N/A YoY) and the FY2015 annual result came in at $45.0 million, changed N/A from the prior year.
- Short-Term Debt issuances fell to -$42.4 million in Q4 2014, from $3.6 million in the prior quarter.
- In the past five years, Short-Term Debt issuances ranged from a high of $3.6 million in Q3 2014 to a low of -$42.4 million in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Travere Therapeutics | 6.11 Bn | 6.11 Bn | 162.52 Mn | - |